The Journal of Obesity & Metabolic Syndrome recently published the results of a randomized, double-blind, and placebo-controlled clinical trial evaluating the supplementation of silymarin among participants with metabolic dysfunction-associated steatotic liver disease (MASLD). This recent nomenclature, MASLD, applies to people with steatotic liver disease that is attributed to the metabolic syndrome; it has considerable overlap…